Junhemeng Biopharmaceutical (Hangzhou) Co Ltd

08/21/2024 | Press release | Archived content

JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity

JHM Biopharmaceutical Receives Approval for Clinical Trial of its Recombinant Type A Botulinum Toxin for Stroke Spasticity

JHM Biopharmaceutical (Hangzhou) Co., Ltd. ("JHM") today announced that it has received approval from the National Medical Products Administration to begin a clinical trial of its injectable Recombinant Type A Botulinum Toxin for the treatment of upper limb spasticity in adult stroke patients.

Junhemeng Biopharmaceutical (Hangzhou) Co Ltd published this content on August 21, 2024, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 29, 2026 at 11:58 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]